Impressive Response of Advanced Hepatocellular Carcinoma to Cisplatin Combined with Sorafenib, Nivolumab, and PG2 Immunomodulatory Injection: A Case Report
{"title":"Impressive Response of Advanced Hepatocellular Carcinoma to Cisplatin Combined with Sorafenib, Nivolumab, and PG2 Immunomodulatory Injection: A Case Report","authors":"Chung-Kuan W, Ping-Hsiu W, Hung-Chih L","doi":"10.4172/2165-7920.10001161","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is an aggressive tumor, and sorafenib is the only proven drug for treating advanced HCC with limited survival outcome. We present a case of severe right lower chest pain in a 54-year-old man. A computed tomography (CT) scan revealed liver cirrhosis and multiple HCCs with inferior vena cava invasion, regional nodal and right adrenal metastases, and hemoperitoneum. His hepatitis B virus (HBV) deoxyribonucleic acid (DNA) level and alpha-fetoprotein (AFP) remained high even after transcutaneous arterial catheter embolization for ruptured HCCs. He received combination therapy of entecavir, sorafenib, nivolumab, cisplatin, and PG2 injection. The follow-up positron emission tomography-CT confirmed no tumor in the liver, and alpha-fetoprotein and HBV DNA titers showed a promising decrease. This novel combination had encouraging therapeutic effects for advanced HCCs, which decreased viral replication without side effects.","PeriodicalId":73664,"journal":{"name":"Journal of clinical case reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2165-7920.10001161","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2165-7920.10001161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Hepatocellular carcinoma (HCC) is an aggressive tumor, and sorafenib is the only proven drug for treating advanced HCC with limited survival outcome. We present a case of severe right lower chest pain in a 54-year-old man. A computed tomography (CT) scan revealed liver cirrhosis and multiple HCCs with inferior vena cava invasion, regional nodal and right adrenal metastases, and hemoperitoneum. His hepatitis B virus (HBV) deoxyribonucleic acid (DNA) level and alpha-fetoprotein (AFP) remained high even after transcutaneous arterial catheter embolization for ruptured HCCs. He received combination therapy of entecavir, sorafenib, nivolumab, cisplatin, and PG2 injection. The follow-up positron emission tomography-CT confirmed no tumor in the liver, and alpha-fetoprotein and HBV DNA titers showed a promising decrease. This novel combination had encouraging therapeutic effects for advanced HCCs, which decreased viral replication without side effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
